Logo image of CBUS

CIBUS INC (CBUS) Stock Fundamental Analysis

NASDAQ:CBUS - Nasdaq - US17166A1016 - Common Stock - Currency: USD

1.5  +0.03 (+2.04%)

After market: 1.54 +0.04 (+2.67%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CBUS. CBUS was compared to 557 industry peers in the Biotechnology industry. Both the profitability and financial health of CBUS have multiple concerns. CBUS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CBUS has reported negative net income.
In the past year CBUS has reported a negative cash flow from operations.
CBUS had negative earnings in each of the past 5 years.
In the past 5 years CBUS always reported negative operating cash flow.
CBUS Yearly Net Income VS EBIT VS OCF VS FCFCBUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of CBUS (-82.03%) is worse than 71.27% of its industry peers.
Looking at the Return On Equity, with a value of -391.10%, CBUS is doing worse than 75.58% of the companies in the same industry.
Industry RankSector Rank
ROA -82.03%
ROE -391.1%
ROIC N/A
ROA(3y)-65.46%
ROA(5y)-69.14%
ROE(3y)-199.52%
ROE(5y)-185.43%
ROIC(3y)N/A
ROIC(5y)N/A
CBUS Yearly ROA, ROE, ROICCBUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CBUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBUS Yearly Profit, Operating, Gross MarginsCBUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

More info and screens

2

2. Health

2.1 Basic Checks

CBUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CBUS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CBUS has been increased compared to 5 years ago.
CBUS has a better debt/assets ratio than last year.
CBUS Yearly Shares OutstandingCBUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CBUS Yearly Total Debt VS Total AssetsCBUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -3.88, we must say that CBUS is in the distress zone and has some risk of bankruptcy.
CBUS has a Altman-Z score of -3.88. This is comparable to the rest of the industry: CBUS outperforms 45.42% of its industry peers.
CBUS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, CBUS perfoms like the industry average, outperforming 44.70% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.88
ROIC/WACCN/A
WACC8.98%
CBUS Yearly LT Debt VS Equity VS FCFCBUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

CBUS has a Current Ratio of 1.23. This is a normal value and indicates that CBUS is financially healthy and should not expect problems in meeting its short term obligations.
CBUS has a worse Current ratio (1.23) than 85.64% of its industry peers.
CBUS has a Quick Ratio of 1.23. This is a normal value and indicates that CBUS is financially healthy and should not expect problems in meeting its short term obligations.
CBUS has a worse Quick ratio (1.23) than 84.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23
CBUS Yearly Current Assets VS Current LiabilitesCBUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.34% over the past year.
Looking at the last year, CBUS shows a very strong growth in Revenue. The Revenue has grown by 104.08%.
The Revenue for CBUS have been decreasing by -10.20% on average. This is quite bad
EPS 1Y (TTM)85.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.93%
Revenue 1Y (TTM)104.08%
Revenue growth 3Y-45.26%
Revenue growth 5Y-10.2%
Sales Q2Q%89.72%

3.2 Future

Based on estimates for the next years, CBUS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.85% on average per year.
CBUS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 137.38% yearly.
EPS Next Y-0.78%
EPS Next 2Y16.04%
EPS Next 3Y9.85%
EPS Next 5Y20.85%
Revenue Next Year34.19%
Revenue Next 2Y49.43%
Revenue Next 3Y178.77%
Revenue Next 5Y137.39%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CBUS Yearly Revenue VS EstimatesCBUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
CBUS Yearly EPS VS EstimatesCBUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CBUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CBUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBUS Price Earnings VS Forward Price EarningsCBUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBUS Per share dataCBUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.04%
EPS Next 3Y9.85%

More info and screens

0

5. Dividend

5.1 Amount

CBUS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CIBUS INC

NASDAQ:CBUS (6/20/2025, 8:20:46 PM)

After market: 1.54 +0.04 (+2.67%)

1.5

+0.03 (+2.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06
Inst Owners24.56%
Inst Owner Change27.76%
Ins Owners8.71%
Ins Owner Change63.09%
Market Cap51.57M
Analysts80
Price Target16.7 (1013.33%)
Short Float %6.53%
Short Ratio5.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.45%
Min EPS beat(2)-12.97%
Max EPS beat(2)-9.92%
EPS beat(4)1
Avg EPS beat(4)11.42%
Min EPS beat(4)-37.98%
Max EPS beat(4)106.57%
EPS beat(8)1
Avg EPS beat(8)-207.02%
EPS beat(12)4
Avg EPS beat(12)-134.41%
EPS beat(16)6
Avg EPS beat(16)-99.97%
Revenue beat(2)1
Avg Revenue beat(2)-2.99%
Min Revenue beat(2)-11.09%
Max Revenue beat(2)5.12%
Revenue beat(4)3
Avg Revenue beat(4)62.06%
Min Revenue beat(4)-11.09%
Max Revenue beat(4)167.48%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.17%
PT rev (3m)-7.09%
EPS NQ rev (1m)-7.19%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-12.35%
EPS NY rev (3m)-20.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-29.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.85
P/FCF N/A
P/OCF N/A
P/B 0.73
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.69
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-1.67
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS0.14
BVpS2.04
TBVpS-5.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.03%
ROE -391.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.46%
ROA(5y)-69.14%
ROE(3y)-199.52%
ROE(5y)-185.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13%
Cap/Sales 18.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z -3.88
F-Score5
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)67.73%
Cap/Depr(5y)64.06%
Cap/Sales(3y)402.26%
Cap/Sales(5y)243.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.93%
EPS Next Y-0.78%
EPS Next 2Y16.04%
EPS Next 3Y9.85%
EPS Next 5Y20.85%
Revenue 1Y (TTM)104.08%
Revenue growth 3Y-45.26%
Revenue growth 5Y-10.2%
Sales Q2Q%89.72%
Revenue Next Year34.19%
Revenue Next 2Y49.43%
Revenue Next 3Y178.77%
Revenue Next 5Y137.39%
EBIT growth 1Y5.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.2%
EBIT Next 3Y29.41%
EBIT Next 5Y22.72%
FCF growth 1Y-251.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-267.6%
OCF growth 3YN/A
OCF growth 5YN/A